Revival of US generic sales not before FY19, say analysts

Sharp fall in Teva's June quarter earnings dash hopes of recovery for domestic pharma firms

An 18 per cent fall in the stock price of the world’s largest generic drug maker, Teva, on Thursday due to an unexpectedly steep price erosion in the US market impacted the top Indian generic companies’ stocks too, which shed up to four per cent intraday on Friday before recovering. While Teva has been bogged down by acquisitions and high debt, the key reason for the sharp negative reaction by the street was the falling price realisations of generic medicines in the US market, which accounts for 40 per cent of Teva’s global sales. US generics revenues for Teva fell